Biotechnology, electronics and life science company MOBILion Systems, Inc. announced on Wednesday a collaboration with Dr Oliver Schmitz from the University of Duisburg-Essen, a specialist in analytical chemistry for complex sample analysis.
This partnership highlights MOBILion's commitment to advancing multiomics research through its proprietary SLIM (Structures for Lossless Ion Manipulation) technology.
Dr Schmitz will integrate MOBILion's latest low mass system into his work on complex sample analysis, including Chinese herbal medicine and multidimensional chromatography workflows. The system addresses limitations of traditional LC-MS and ion mobility technologies, enabling precise and efficient metabolomics discovery. Cleaner, more focused data is achieved by reducing overlapping signals, simplifying molecular identification and interpretation.
MOBILion continues to expand its SLIM-based product pipeline, supporting breakthroughs in proteomics, lipidomics, glycomics, and metabolomics. This collaboration builds on the company's recent progress in proteomics applications and commercial platform development.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA